Marc A. Cohen co-founded C4 Therapeutics, Inc. and has been the Executive Chairman since its inception in 2015. He served as the interim CEO in 2020 during a crucial phase when the company was transitioning towards its IPO. Marc's background...

Marc A. Cohen co-founded C4 Therapeutics, Inc. and has been the Executive Chairman since its inception in 2015. He served as the interim CEO in 2020 during a crucial phase when the company was transitioning towards its IPO. Marc's background includes significant roles in other biotech companies, indicating his deep involvement in the life sciences sector. After his interim CEO role, he continued to shape the company as Executive Chairman. Notably, he did not take a salary for his CEO position in 2020, reflecting a commitment to aligning his interests with the company’s growth. His experience includes leadership at various companies focused on innovative therapies, showcasing his strategic vision in the biotech field. Cohen also has a strong technical background, holding advanced degrees in electrical engineering from prestigious institutions like Stanford and Harvard. Beyond his corporate duties, he is involved in philanthropy, co-founding a cancer research fund. His ability to balance leadership with a focus on progress makes him an influential figure at C4 Therapeutics, guiding it through its next stages.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other C4 Therapeutics CEOs

C

Marc A. Cohen

Ex-CEO of C4 Therapeutics

Sector of Economy

Healthcare

CEO of C4 Therapeutics for

0 years 0 months (Oct 2020 - Oct 2020)

Previous Experience

Unknown

Rivals

Competitors/colleagues of Marc A. Cohen

Holdings

See how much did Marc A. Cohen make over time.

Marc A. Cohen's financial journey with C4 Therapeutics is remarkable, especially in the context of his stock performance after the company's IPO in 2020. Initially, by October 2020, the value of his shares was estimated at approximately $109.67 million, but...

Marc A. Cohen's financial journey with C4 Therapeutics is remarkable, especially in the context of his stock performance after the company's IPO in 2020. Initially, by October 2020, the value of his shares was estimated at approximately $109.67 million, but within the following months, this value saw a notable increase, peaking around $184.80 million in February 2021. However, the stock value then fluctuated, dropping down to around $79.84 million by August 2021, showcasing the volatile nature of biotech stocks. As of late 2022, the value of his holdings diminished significantly, reaching as low as $14.58 million, proving that the biotech market can be unpredictable. Nonetheless, his role as an executive and his stock holdings demonstrate his strong commitment to the long-term vision of C4 Therapeutics.

Loading...

Insider Trading

See recent insider trades of Marc A. Cohen.

CCCC

$20.75K

CCCC at $31.58/share

Jan 4, 2022

Received

CCCC

$20.74K

CCCC at $44.99/share

Oct 4, 2021

Received

CCCC

$20.73K

CCCC at $39.72/share

Jul 2, 2021

Received

CCCC

$20.74K

CCCC at $37.51/share

Apr 5, 2021

Received

CCCC

$95.57K

CCCC at $19.00/share

Oct 6, 2020

Purchase

Compensation History

See how much did Marc A. Cohen make over time.

In 2020, Marc A. Cohen did not receive a salary as the interim CEO of C4 Therapeutics, which reflects a unique approach to executive compensation that ties leadership to performance rather than typical cash payouts. Instead, his total reported compensation for that year was $69,500, primarily from his director fees. He was granted stock options valued at 725,002 shares, indicating a focus on equity incentives that align with shareholders' interests. This method emphasizes long-term growth rather than short-term gains. His decision to forgo a cash salary during his interim CEO tenure could be seen as a strategic move designed to instill confidence in the company, particularly amid its IPO process, showing that he is looking at both the company’s health and his personal financial stake in the business. This structure aligns with his overall compensation philosophy that promotes company performance while attracting talented management.

Year

2020

Total Compensation

$69.50K

Salary

$0.00

Board Justification

The compensation philosophy aligns with company performance and aims to attract and retain qualified individuals.

Bonus

$0.00

Board Justification

Marc A. Cohen did not receive any cash compensation in connection with his service as our interim Chief Executive Officer during 2020.

Other

$69.50K

Board Justification

This amount represents cash fees paid to Mr. Cohen for his service as a director.

Restricted Stock

$0.00(725K stock options)

Board Justification

Mr. Cohen was granted a stock option to purchase 725,002 shares of our common stock in recognition of his past and future service as our Executive Chairman and interim Chief Executive Officer during 2020, 12.5% of which award vested on April 1, 2021 and the balance of which award vests in 14 equal quarterly installments thereafter.

Performance Metrics

N/A

Other C4 Therapeutics CEOs

Here are other CEOs of C4 Therapeutics

Kendra Adams

CEO of C4 Therapeutics

September 2023 - Present